Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era

Journal of Clinical Oncology

Volumn 28, Issue 14, 2010, Pages 2373-2380

  Ziepert, Marita ^a   Hasenclever, Dirk ^a   Kuhnt, Evelyn ^a   Glass, Bertram ^a   Schmitz, Norbert ^a   Pfreundschuh, Michael ^a   Loeffler, Markus ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; EVENT FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STANDARD; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT OUTCOME; ADOLESCENT; AGED; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; HEALTH SURVEY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEALTH STATUS INDICATORS; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77952477025     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.2493     Document Type: Article

References (33)

1. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
2. Shipp MA: Prognostic factors in aggressive Non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83:1165-1173, 1994
3. McKelvey EM, Gottlieb JA, Wilson HE, et al: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976
4. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993 (Pubitemid 23095683)
5. Pfreundschuh M, Trümper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004 (Pubitemid 38970553)
6. Pfreundschuh M, Trümper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004 (Pubitemid 38970554)
7. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
8. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
9. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
10. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
11. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
12. Loeffler M, Shipp M, Stein H: 2. Report on the workshop: "Clinical consequences of pathology and prognostic factors in aggressive NHL." Ann Hematol 80:B8-B12, 2001
13. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007
14. Glass B, Kloess M, Bentz M, et al: Doseescalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 107:3058-3064, 2006
15. Schmitz N, Kloess M, Reiser M, et al: Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer 106:136-145, 2006 (Pubitemid 43032558)
16. Glass B, Kloess M, Reiser M, et al: Dose escalated CHOP plus etoposide followed by repetitive autologous stem cell transplantation (Mega-CHOEP) with or without rituximab for primary treatment of aggressive NHL. Blood 106:430A, 2005 (abstr 1492)
17. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
18. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours, Volume 3. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, Franc, IARC Press, 2001
19. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989 (Pubitemid 19272832)
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665-1677, 1991
22. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
23. de Jong D, Rosenwald A, Chhanabhai M, et al: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications-A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25:805-812, 2007 (Pubitemid 350002880)
24. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al: Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930-4935, 2007 (Pubitemid 46827791)
25. Schmitz N, Nickelsen M, Ziepert M, et al: Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: Results of the MegaCHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 114:168, 2009 (abstr 404)
26. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000 (Pubitemid 30082188)
27. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
28. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002 (Pubitemid 34101731)
29. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:9991-9996, 2003 (Pubitemid 37087056)
30. Abramson JS, Shipp MA: Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. Blood 106:1164-1174, 2005 (Pubitemid 41129574)
31. Lossos IS: Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 23:6351-6357, 2005
32. Lossos IS, Morgensztern D: Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995-1007, 2006 (Pubitemid 46638855)
33. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-cell lymphomas. N Engl J Med 359:2313-2323, 2008